Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J591 in Advanced Prostate Cancer with Unfavorable CTCs
NCT02552394Phase 1Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Jul 2015
- Primary completion
- Nov 2019
- Modality
- Engineered Antibody Formats, Antibody-Radionuclide Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of huJ591 in prostate cancer (PCa), sponsored by Weill Cornell Medicine. Primary endpoint: Changes in frequency of achieving a decrease in Circulating tumor count (CTC). Started Jul 2015; status: completed.
02
Drugs
huJ591
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02552394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02552394.